Paraquat exposure reduces nicotinic receptor-evoked dopamine release in monkey striatum.
Level 5 - mechanism / opinion, no new human data
Animal research (non-human primate model)
PubMed 18606871 · doi:10.1124/jpet.108.141861
What was done
Monkeys were administered saline or paraquat once weekly for 6 weeks. Following exposure, investigators measured striatal nicotinic acetylcholine receptor (nAChR) expression levels and receptor-evoked [3H]dopamine release, specifically assessing alpha3/alpha6beta2* and alpha4beta2* nAChR subtypes.
What was found
The abstract reports no numerical data. Paraquat exposure attenuated dopamine release evoked by alpha3/alpha6beta2* nAChRs, with no decline in dopamine release mediated by alpha4beta2* nAChRs. In contrast, paraquat treatment decreased alpha4beta2* nAChR expression but did not alter alpha3/alpha6beta2* nAChR expression.
Why it matters
These findings show that paraquat directly impairs functional dopamine release mediated by terminal nicotinic receptors in non-human primates, demonstrating functional susceptibility not observed in prior mouse models.
Limits
The abstract does not state the number of monkeys (n), dose of paraquat administered, or quantitative effect sizes and variance. Findings from non-human primates cannot directly establish clinical toxicity thresholds or causal timelines for human Parkinson's disease.
Cited by
- supports Paraquat is used experimentally in research laboratories to induce Parkinson's disease in non-human primates.